Artemisinin Antimalarial Drugs Market Analysis

  • Report ID: 6615
  • Published Date: Oct 30, 2024
  • Report Format: PDF, PPT

Artemisinin Antimalarial Drugs Market Analysis

Product (Antimalarial Injections, Antimalarial Tablets)

Antimalarial tablets segment is likely to account for more than 80.1% artemisinin antimalarial drugs market share by the end of 2037.The ongoing innovations in antimalarial tablet formulations are promoting their sales growth. The easy administration and high potential results are majorly driving the consumption of antimalarial tablets. Travelers often get affected by mosquito-related diseases including, malaria and to avoid any serious effects, they rely on antimalarial tablets. For instance, according to the U.S. Department of Veterans Affairs, mefloquine a white round tablet can help travelers to get cured of malaria infections.

Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi)

The plasmodium falciparum segment in artemisinin antimalarial drugs market is anticipated to capture a significant share of the global revenue by 2037 owing to the high prevalence of plasmodium falciparum and its severity. Plasmodium falciparum is a dominant parasite and accounts for a 65.8% prevalence rate, globally. Thus, such a high prevalence rate substantially drives the need for advanced medications including artemisinin-based combination therapies. Underdeveloped countries in Asia Pacific and MEA are particularly driving high demand for artemisinin antimalarial medications.

Our in-depth analysis of the global market includes the following segments:

Product

  • Antimalarial Injections
  • Antimalarial Tablets

 

Malaria Type

  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Plasmodium Ovale
  • Plasmodium Malariae
  • Plasmodium Knowlesi

Type

  • Monotherapy
  • Combination Therapy
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6615
  • Published Date: Oct 30, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global artemisinin antimalarial drugs market will be valued at 734.1 million in 2025.

Expanding at a CAGR of 4.5%, the global market is expected to increase from USD 702.5 million in 2024 to USD 1.24 billion by 2037.

Some leading companies are Cipla Limited, Novartis AG, Sanofi S.A., GlaxoSmithKline Pharmaceuticals Ltd, Shanghai Desano Pharmaceutical Group Co., Ltd, Mylan N.V., and Shanghai Fosun Pharmaceutical Co., Ltd.

The antimalarial tablet segment is estimated to capture a strong 80.1% of the market share through 2037.

Middle East and Africa is expected to hold 33.8% of the global market share through 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample